Avion Wealth’s Travere Therapeutics TVTX Stock Holding History

Avion Wealth’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-7	Closed	–	–	1709
2026 Q2	$0	Buy	+7	New	+$310	﹤0.01%	1745

Other funds holding TVTX

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Stephens Investment Management Group Houston, Texas $9.29B AUM 41.16% 1-Year Est. Return

Emerald Advisers Leola, Pennsylvania $3.64B AUM 71.19% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.45B AUM 70.46% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return

Fiera Capital (Canada) Montreal, Quebec, Canada $25.3B AUM 15.9% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return

Avion Wealth's TVTX Position: Q3 2026 in Review

Avion Wealth sold out of Travere Therapeutics (TVTX) in Q3 2026, closing a stake of 7 shares.

Avion Wealth first reported a position in TVTX in Q2 2026 and held it in 1 quarter. The position peaked at $0 in Q2 2026. 158 funds tracked by Wall St. Rank hold TVTX as of Q3 2026.

Avion Wealth reported no remaining Travere Therapeutics position as of Q3 2026 after selling out during the quarter.
Avion Wealth sold 7 Travere Therapeutics shares in Q3 2026.
Avion Wealth first reported a position in Travere Therapeutics in Q2 2026 and held it in 1 quarter.
Avion Wealth's Travere Therapeutics position peaked at $0 in Q2 2026.
158 funds tracked by Wall St. Rank held Travere Therapeutics as of Q3 2026.

Based on Avion Wealth's 13F filing for Q3 2026, filed 4 Nov 2026.